«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2022 04

Page:

603-607

Research Field:

Publishing date:

Info

Title:

The expression and mechanism of IKZF1 gene in BCR/ABL fusion gene positive acute lymphoblastic leukemia

Author(s):

LIU Feng; WEN Jing; LI Guang; DAI Jinqian; DU Mingzhu; SONG Yanping

Institute of Hematology of Xi'an,Xi'an Central Hospital,Shaanxi Xi'an 710004,China.

Keywords:

acute lymphoblastic leukemia; BCR/ABL; IKZF1; IK6; cRSS; recombination activating gene protein

PACS:

R733.71

DOI:

10.3969/j.issn.1672-4992.2022.04.009

Abstract:

Objective:To explore the expression characteristics and possible mechanism of IKZF1 gene in acute lymphoblastic leukemia,and to further clarify the pathogenesis of acute lymphoblastic leukemia.Methods:Peripheral blood samples of 80 patients with acute lymphoblastic leukemia were collected,of which 21 patients were positive for BCR/ABL fusion gene,all of which were B-cell acute lymphoblastic leukemia.RT-PCR technology detected the expression of IKZF1 gene,RAG1 gene and RAG2 gene.Cell DNA was extracted.PCR technology detected the deletion mutation of IKZF1 gene.Second-generation sequencing was used to understand the base sequence of the breakpoint region of IKZF1 gene.Results:RT-PCR result showed 19 patients of 80 patients with acute lymphoblastic leukemias expressed IK6 subtype.Among these 19 cases,17 of whom were BCR/ABL fusion gene-positive B-cell acute lymphoblastic leukemia,and 2 of whom were BCR/ABL fusion gene-negative B-cell acute lymphoblastic leukemia.That was,the expression of IK6 subtype was mainly in B-cell acute lymphoblastic leukemia,and was mainly related to the BCR/ABL fusion gene.PCR experiment confirmed that the deletion mutation of IKZF1 gene in B-cell acute lymphoblastic leukemia with positive BCR/ABL fusion gene.Second-generation sequencing revealed that the IK6 subtype was formed by abnormally splitting and splicing between intron 2 and intron 6 of IKZF1 gene,and there was a cRSS sequence that can be targeted by recombination activating gene protein at the break point.Conclusion:The expression of IK6 subtype is mainly in B-cell acute lymphoblastic leukemia.The expression of IK6 subtype is related to the BCR/ABL fusion gene in acute lymphoblastic leukemia.The expression of IK6 subtype in BCR/ABL fusion gene-positive acute lymphoblastic leukemia may be related to the rupture of introns 2 and 6 of IKZF1 gene caused by the targeting of recombination activating gene protein.

References:

[1]HUNGER SP,MULLIGHAN CG.Redefining ALL classification:toward detecting high-risk ALL and implementing precision medicine£ÛJ£Ý.Blood,2015,125(26):3977-3987.
[2]CHURCHMAN ML,MULLIGHAN CG.IKAROS:Exploiting and targeting the hematopoietic stem cell niche in B-progenitor acute lymphoblastic leukemia£ÛJ£Ý.Exp Hematol,2017,46:1-8.
[3]LI S,ILARIA RL,MILLION RP,et al.The P190,P210,and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity£ÛJ£Ý.J Exp Med,1999,189:1399-1412.
[4]WANG H,SONG C,DING Y,et al.Transcriptional regulation of JARID1B/KDM5B histone demethylase by IKAROS,histone deacetylase 1 (HDAC1),and casein kinase 2 (CK2) in B-cell acute lymphoblastic leukemia£ÛJ£Ý.J Biol Chem,2016,291(8):4004-4018.
[5]STANULLA M,CAV¦I H,MOORMAN AV.IKZF1 deletions in pediatric acute lymphoblastic leukemia:still a poor prognostic marker£ÛJ£Ý.Blood,2020,135(4):252-260.
[6]MARKE R,VAN LEEUWEN FN,SCHEIJEN B.The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia£ÛJ£Ý.Haematologica,2018,103:565-574.
[7]GE Z,GU Y,HAN Q,et al.Plant homeodomain finger protein 2 as a novel IKAROS target in acute lymphoblastic leukemia£ÛJ£Ý.Epigenomics,2018,10(1):59-69.
[8]VAIRY S,TRAN TH.IKZF1 alterations in acute lymphoblastic leukemia:the good,the bad and the ugly£ÛJ£Ý.Blood Rev,2020,44:100677.
[9]CUI L,GAO C,WANG CJ,et al.Combined analysis of IKZF1 deletionsand CRLF2 expression on prognostic impact in pediatric B-cell precursor acute lymphoblastic leukemia£ÛJ£Ý.Leuk Lymphoma,2021,62(2):410-418.
[10]DING Y,ZHANG B,PAYNE JL,et al.Ikaros tumor suppressor function includes induction of active enhancers and super-enhancers along with pioneering activity£ÛJ£Ý.Leukemia,2019,33(11):2720-2731.
[11]GE Z,ZHOU X,GU Y,et al.IKAROS regulation of the BCL6/BACH2 axis and its clinical relevance in acute lymphoblastic leukemia£ÛJ£Ý.Oncotarget,2017,8(5):8022-8034.
[12]GE Z,HAN Q,GU Y,et al.Aberrant ARID5B expression and its association with Ikaros dysfunction in acute lymphoblastic leukemia£ÛJ£Ý.Oncogenesis,2018,7(11):84.
[13]ROMAN-GOMEZ J,JIMENEZ-VELASCO A,AGIRRE X,et al.Epigenetic regulation of PRAME gene in chronic myeloid leukemia£ÛJ£Ý.Leuk Res,2007,31(11):1521-1528.
[14]FALINSKI R,NIEBOROWSKA-SKORSKA M,SKORSKI T.BCR-ABL1 kinase facilitates localization of acetylated histones 3 and 4 on DNA double-strand breaks£ÛJ£Ý.Leuk Res,2012,36(2):241-244.
[15]MIJUSKOVIC M,CHOU YF,GIGI V,et al.Off-target V(D)J recombination drives lymphomagenesis and is escalated by loss of the Rag2 C terminus£ÛJ£Ý.Cell Rep,2015,12(11):1842-1852.
[16]HUANG L,LANGE MD,YU Y,et al.Contribution of V(H) replacement products in mouse antibody repertoire£ÛJ£Ý.PLoS One,2013,8(2):e57877.
[17]KRANGEL MS.T cell development:better living through chromatin£ÛJ£Ý.Nature Immunology,2007,8:687-694.
[18]SCHLISSEL MS.Regulating antigen-receptor gene assembly£ÛJ£Ý.Nature Reviews Immunology,2003,3:890-899.
[19]KIRKHAM CM,BOYES J.Genome instability triggered by the V(D)J recombination by-product£ÛJ£Ý.Mol Cell Oncol,2019,6(4):1610323.

Memo

Memo:

ÉÂÎ÷Ê¡Î÷°²ÊпƼ¼¼Æ»®ÏîÄ¿£Û±àºÅ£º201805095YX3SF29(3)£Ý

Common functions

Last Update: 1900-01-01